NASDAQ:EVAX Evaxion Biotech A/S (EVAX) Stock Price, News & Analysis $3.09 -0.27 (-8.04%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends About Evaxion Biotech A/S Stock (NASDAQ:EVAX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Evaxion Biotech A/S alerts:Sign Up Key Stats Today's Range$3.03▼$3.4950-Day Range$0.85▼$12.1052-Week Range$3.03▼$68.05Volume59,446 shsAverage Volume974,021 shsMarket Capitalization$18.14 millionP/E RatioN/ADividend YieldN/APrice Target$55.00Consensus RatingBuy Company OverviewEvaxion Biotech A/S, a clinical-stage biotech company, engages in developing artificial intelligence-powered immunotherapies. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based vaccine that is in Phase 1/2a trial designed to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers. Its programs also include some vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, viral vaccine product candidate for targeting Cytomegalovirus. Evaxion Biotech A/S was incorporated in 2008 and is based in Horsholm, Denmark.Read More… Evaxion Biotech A/S Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks50th Percentile Overall ScoreEVAX MarketRank™: Evaxion Biotech A/S scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingEvaxion Biotech A/S has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEvaxion Biotech A/S has only been the subject of 1 research reports in the past 90 days.Read more about Evaxion Biotech A/S's stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Evaxion Biotech A/S are expected to grow in the coming year, from ($0.15) to ($0.11) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Evaxion Biotech A/S is -10.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Evaxion Biotech A/S is -10.66, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Evaxion Biotech A/S's valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted16.70% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently increased by 709.33%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldEvaxion Biotech A/S does not currently pay a dividend.Dividend GrowthEvaxion Biotech A/S does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted16.70% of the outstanding shares of Evaxion Biotech A/S have been sold short.Short Interest Ratio / Days to CoverEvaxion Biotech A/S has a short interest ratio ("days to cover") of 2.9, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Evaxion Biotech A/S has recently increased by 709.33%, indicating that investor sentiment is decreasing significantly. News and Social Media2.2 / 5News Sentiment-0.03 News SentimentEvaxion Biotech A/S has a news sentiment score of -0.03. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 13 news articles for Evaxion Biotech A/S this week, compared to 2 articles on an average week.Search Interest6 people have searched for EVAX on MarketBeat in the last 30 days. MarketBeat Follows1 people have added Evaxion Biotech A/S to their MarketBeat watchlist in the last 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Evaxion Biotech A/S insiders have not sold or bought any company stock.Percentage Held by Insiders41.64% of the stock of Evaxion Biotech A/S is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 11.04% of the stock of Evaxion Biotech A/S is held by institutions.Read more about Evaxion Biotech A/S's insider trading history. Receive EVAX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Evaxion Biotech A/S and its competitors with MarketBeat's FREE daily newsletter. Email Address EVAX Stock News HeadlinesResearch Analysts Issue Forecasts for EVAX FY2024 EarningsJanuary 18 at 1:14 AM | americanbankingnews.comEvaxion Biotech stock hits 52-week low at $3.06 amid sharp declineJanuary 17, 2025 | msn.comTesla Shares Soar After Trump Win (Act Now)Are you ready to see why Tesla might be the biggest opportunity on the market today? Right now, Tesla stock is at a critical juncture, and Lance believes it’s primed for explosive growth. That’s why he’s giving away his eBook, The Bullish Case for Tesla, for FREE—but only for a limited time.January 21, 2025 | WealthPress (Ad)Evaxion Biotech: Evaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01January 16, 2025 | finanznachrichten.deEvaxion Biotech completes dosing in phase 2 trial with EVX-01January 16, 2025 | markets.businessinsider.comEvaxion concludes subject dosing in Phase II trial of melanoma vaccineJanuary 16, 2025 | finance.yahoo.comEvaxion Biotech Completes Dosing In Phase 2 Trial For Personalized Cancer Vaccine EVX-01January 16, 2025 | markets.businessinsider.comEvaxion completes dosing in phase 2 trial with personalized cancer vaccine EVX-01January 15, 2025 | markets.businessinsider.comSee More Headlines EVAX Stock Analysis - Frequently Asked Questions How have EVAX shares performed this year? Evaxion Biotech A/S's stock was trading at $4.2270 at the beginning of the year. Since then, EVAX shares have decreased by 26.9% and is now trading at $3.09. View the best growth stocks for 2025 here. How were Evaxion Biotech A/S's earnings last quarter? Evaxion Biotech A/S (NASDAQ:EVAX) issued its quarterly earnings results on Thursday, October, 31st. The company reported ($0.20) earnings per share for the quarter, beating analysts' consensus estimates of ($0.60) by $0.40. The company earned $3.02 million during the quarter, compared to analysts' expectations of $0.19 million. When did Evaxion Biotech A/S's stock split? Evaxion Biotech A/S shares reverse split before market open on Monday, January 13th 2025. The 1-5 reverse split was announced on Monday, December 30th 2024. The number of shares owned by shareholders was adjusted after the market closes on Friday, January 10th 2025. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split. When did Evaxion Biotech A/S IPO? Evaxion Biotech A/S (EVAX) raised $31 million in an initial public offering on Friday, February 5th 2021. The company issued 2,800,000 shares at a price of $10.00-$12.00 per share. Oppenheimer & Co. acted as the underwriter for the IPO and Ladenburg Thalmann was co-manager. How do I buy shares of Evaxion Biotech A/S? Shares of EVAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Evaxion Biotech A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Evaxion Biotech A/S investors own include PayPal (PYPL), Arista Networks (ANET), Tesla (TSLA), ChargePoint (CHPT), MercadoLibre (MELI), ASML (ASML). Company Calendar Last Earnings10/31/2024Today1/20/2025Next Earnings (Estimated)3/26/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:EVAX CUSIPN/A CIK1828253 Webwww.evaxion-biotech.com Phone45-5353-1850FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$55.00 High Stock Price Target$70.00 Low Stock Price Target$40.00 Potential Upside/Downside+1,679.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,120,000.00 Net Margins-347.83% Pretax Margin-368.80% Return on EquityN/A Return on Assets-79.40% Debt Debt-to-Equity Ratio7.99 Current Ratio1.00 Quick Ratio2.80 Sales & Book Value Annual Sales$70,000.00 Price / Sales259.12 Cash FlowN/A Price / Cash FlowN/A Book Value($1.17) per share Price / Book-2.64Miscellaneous Outstanding Shares5,870,000Free Float3,423,000Market Cap$18.14 million OptionableNo Data Beta-0.23 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report This page (NASDAQ:EVAX) was last updated on 1/21/2025 by MarketBeat.com Staff From Our PartnersCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredStunning Trump Exec Order LeakedThis secret document contains stunning details about Donald Trump’s very first order of business… the minute h...Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode in 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredBuy this coin BEFORE Inauguration Day …Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $1...Weiss Ratings | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe crypto bull market is here, and the stakes couldn’t be higher. The next 3-6 months? They’re the most ex...Crypto Swap Profits | SponsoredMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines ab...Brownstone Research | SponsoredElon’s New AI Firm REVEALEDNvidia’s AI chip … the H100 … has been the holy grail of artificial intelligence… Until now. Because Elo...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Evaxion Biotech A/S Please log in to your account or sign up in order to add this asset to your watchlist. Share Evaxion Biotech A/S With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
